ABBV-RGX-314 Dose 1 Clinical Trials (2026): 9 Studies for Neovascular Age-related Macular Degeneration & Wet Age-related Macular Degeneration
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
9 ABBV-RGX-314 Dose 1 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 5 indications (including Neovascular Age-related Macular Degeneration & Wet Age-related Macular Degeneration) and 3,237 total planned enrollment. 2 Phase 3 ABBV-RGX-314 Dose 1 trials and 5 Phase 2 are listed. 3 ABBV-RGX-314 Dose 1 clinical trials are actively recruiting at 52 U.S. sites across 20 states. Most recent activity: NCT07007065 (Mar 2033).
Where to Participate: All ABBV-RGX-314 Dose 1 Trial Sites in the U.S. (52 sites across 20 states)
Every actively recruiting ABBV-RGX-314 Dose 1trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.
| State | Facility | City | Trial | Map |
|---|---|---|---|---|
| AZ | Barnet Dulaney Perkins Eye Centers /ID# 279265 | Mesa85206 | NCT07007065 | Map |
| AZ | American Vision Partners /ID# 264615 | Sun City85351 | NCT07007065 | Map |
| CA | Retinal Diagnostic Center /ID# 263054 | Campbell95008 | NCT07007065 | Map |
| CA | The Retina Partners /ID# 263265 | Encino91436 | NCT07007065 | Map |
| CA | Retina Associates of Southern California /ID# 263056 | Huntington Beach92647 | NCT07007065 | Map |
| CA | Northern California Retina Vitreous Associates - Mountain View /ID# 263990 | Mountain View94040-4119 | NCT07007065 | Map |
| CA | Eye Research Foundation /ID# 277345 | Newport Beach92663 | NCT07007065 | Map |
| CA | Retina Consultants of San Diego /ID# 264026 | Poway92064-2530 | NCT07007065 | Map |
| CA | Retina Consultants Of Southern California - Redlands /ID# 276496 | Redlands92374 | NCT07007065 | Map |
| CA | Kaiser Permanente - Riverside Medical Center /ID# 263253 | Riverside92505 | NCT07007065 | Map |
| CA | Retinal Consultants - Sacramento - Greenback Lane /ID# 263983 | Sacramento95841 | NCT07007065 | Map |
| CA | UCSF, Wayne and Gladys Valley Center for Vision /ID# 263058 | San Francisco94143-2510 | NCT07007065 | Map |
| CA | Orange County Retina Medical Group /ID# 266612 | Santa Ana92705 | NCT07007065 | Map |
| CO | Retina Consultants of Southern Colorado /ID# 263284 | Colorado Springs80909 | NCT07007065 | Map |
| CO | Colorado Retina Associates /ID# 263247 | Lakewood80228 | NCT07007065 | Map |
| CO | Advanced Vision Surgery Center /ID# 264208 | Longmont80503 | NCT07007065 | Map |
| FL | Advanced Research, LLC /ID# 276526 | Deerfield Beach33064-1346 | NCT07007065 | Map |
| FL | Segal Drug Trials, Inc /ID# 276966 | Delray Beach33484 | NCT07007065 | Map |
| FL | Retina Vitreous Consultants LLP business DBA as Retina Group of Florida /ID# 264631 | Fort Myers33917 | NCT07007065 | Map |
| FL | Florida Retina Institute - Lake Mary /ID# 263288 | Lake Mary32746 | NCT07007065 | Map |
| FL | Center for Retina and Macular Disease /ID# 264201 | Winter Haven33880 | NCT07007065 | Map |
| GA | Southeast Retina Center /ID# 263264 | Augusta30909 | NCT07007065 | Map |
| IL | Vision Medical Research /ID# 277102 | Oak Lawn60453 | NCT07007065 | Map |
| IL | Springfield Clinic Main Campus /ID# 265202 | Springfield62703-2403 | NCT07007065 | Map |
| IN | Midwest Eye Institute North Indianapolis /ID# 264031 | Carmel46290 | NCT07007065 | Map |
| IA | Wolfe Eye Clinic - West Des Moines /ID# 263270 | West Des Moines50266 | NCT07007065 | Map |
| ME | Maine Eye Center - Marginal Way Campus /ID# 263251 | Portland04101 | NCT07007065 | Map |
| MD | The Retina Care Center /ID# 263263 | Baltimore21209 | NCT07007065 | Map |
| MD | Retina Specialist /ID# 264633 | Towson21204 | NCT07007065 | Map |
| MI | Associated Retinal Consultants /ID# 263289 | Royal Oak48073 | NCT07007065 | Map |
| MN | Retina Consultants of Minnesota (RCM) - Edina Retina Clinic /ID# 279427 | Edina55435 | NCT07007065 | Map |
| MN | Mayo Clinic - Minnesota /ID# 263977 | Rochester55905 | NCT07007065 | Map |
| MO | Retina Institute - St. Louis /ID# 263985 | St Louis63128 | NCT07007065 | Map |
| NV | Sierra Eye Associates | Reno89502 | NCT06942520 | Map |
| NJ | Monmouth Retina Consultants /ID# 279252 | Little Silver07739 | NCT07007065 | Map |
| OH | Cleveland Clinic - Cleveland /ID# 264210 | Cleveland44195 | NCT07007065 | Map |
| OH | Ohio State Havener Eye Institute - Columbus /ID# 263987 | Columbus43212 | NCT07007065 | Map |
| OH | Midwest Retina /ID# 263231 | Dublin43016 | NCT07007065 | Map |
| PA | Erie Retina Research /ID# 263287 | Erie16507 | NCT07007065 | Map |
| PA | Mid Atlantic Retina /ID# 263291 | Philadelphia19107 | NCT07007065 | Map |
| SC | Charleston Neuroscience Institute - Bluffton /ID# 264037 | Bluffton29910 | NCT07007065 | Map |
| SC | Charleston Neuroscience Institute - Charleston /ID# 276425 | Charleston29414 | NCT07007065 | Map |
| SC | Retina Consultants of South Carolina - Ladson /ID# 277596 | Ladson29456 | NCT07007065 | Map |
| SC | Retina Consultants of America /ID# 264038 | Mt. Pleasant29464 | NCT07007065 | Map |
| TX | Retina Research Institute of Texas /ID# 263233 | Abilene79606 | NCT07007065 | Map |
| TX | Austin Clinical Research, LLC /ID# 263229 | Austin78750-2298 | NCT07007065 | Map |
| TX | Austin Retina Associates - Austin /ID# 266770 | Austin78705 | NCT07007065 | Map |
| TX | Star Retina /ID# 266386 | Burleson76028 | NCT07007065 | Map |
| TX | Retina Consultants of Texas /ID# 263274 | Houston77056-3030 | NCT07007065 | Map |
| TX | Austin Retina Associates - Round Rock /ID# 266776 | Round Rock78681 | NCT07007065 | Map |
| TX | Retina Consultants of Texas - Westover /ID# 264209 | San Antonio78251 | NCT07007065 | Map |
| UT | Rocky Mountain Retina Consultants /ID# 263266 | Murray84107 | NCT07007065 | Map |
ABBV-RGX-314 Dose 1 clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | Total |
|---|---|---|---|---|---|
| P1/P2 | 1 | 1 | |||
| P2 | 1 | 2 | 1 | 1 | 5 |
| P2/P3 | 1 | 1 | |||
| P3 | 1 | 1 | 2 |
Recruiting ABBV-RGX-314 Dose 1 clinical trials (3)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07007065 | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | P3 | Neovascular Age-related Macular Degeneration | 561 | Nov 2025 |
| NCT03999801 | RGX-314 SRLTFULong-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | P2 | Neovascular Age-related Macular Degeneration | 865 | May 2019 |
| NCT06942520 | ELAAVATEPhase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME) | P2 | Diabetic Macular Edema | 18 | Mar 2025 |
ABBV-RGX-314 Dose 1 clinical trials by indication
Neovascular Age-related Macular Degeneration (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07007065 | — | P3 | recruiting | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
| NCT03999801 | RGX-314 SRLTFU | P2 | enrolling by invitation | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy |
| NCT04832724 | — | P2 | completed | RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) |
| NCT03066258 | — | P1/P2 | completed | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial |
AMD (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05407636 | ASCENT | P3 | active not recruiting | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD |
| NCT04704921 | ATMOSPHERE | P2/P3 | active not recruiting | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD |
Diabetic Macular Edema (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06942520 | ELAAVATE | P2 | recruiting | Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME) |
Diabetic Retinopathy (DR) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04567550 | ALTITUDE® | P2 | active not recruiting | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) |
Neovascular Age-Related Macular Degeneration (nAMD) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04514653 | AAVIATE | P2 | active not recruiting | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
ABBV-RGX-314 Dose 1 pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| ASCENT | NCT05407636 | P3 | active not recruiting | AMD | 735 | — |
| RGX-314 SRLTFU | NCT03999801 | P2 | enrolling by invitation | Neovascular Age-related Macular Degeneration | 865 | — |
| ELAAVATE | NCT06942520 | P2 | recruiting | Diabetic Macular Edema | 18 | — |
| AAVIATE | NCT04514653 | P2 | active not recruiting | Neovascular Age-Related Macular Degeneration (nAMD) | 146 | — |
| ALTITUDE® | NCT04567550 | P2 | active not recruiting | Diabetic Retinopathy (DR) | 139 | — |
All ABBV-RGX-314 Dose 1 trials (9)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07007065 | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | P3 | recruiting | 561 | AbbVie | Nov 2025 | |
| NCT03999801 | RGX-314 SRLTFU | Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy | P2 | enrolling by invitation | 865 | AbbVie | May 2019 |
| NCT06942520 | ELAAVATE | Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME) | P2 | recruiting | 18 | Sierra Eye Associates | Mar 2025 |
| NCT05407636 | ASCENT | Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD | P3 | active not recruiting | 735 | AbbVie | Jan 2022 |
| NCT04704921 | ATMOSPHERE | Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD | P2/P3 | active not recruiting | 671 | AbbVie | Dec 2020 |
| NCT04514653 | AAVIATE | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD) | P2 | active not recruiting | 146 | AbbVie | Aug 2020 |
| NCT04567550 | ALTITUDE® | RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME) | P2 | active not recruiting | 139 | AbbVie | Nov 2020 |
| NCT04832724 | RGX-314 Gene Therapy Pharmacodynamic Study for Neovascular Age-related Macular Degeneration (nAMD) | P2 | completed | 60 | AbbVie | Feb 2021 | |
| NCT03066258 | Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial | P1/P2 | completed | 42 | REGENXBIO Inc. | Mar 2017 |
ABBV-RGX-314 Dose 1 clinical trials: frequently asked questions
- How many ABBV-RGX-314 Dose 1 clinical trials are there?
- 9 ABBV-RGX-314 Dose 1 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 3 are actively recruiting participants. 2 are marked completed.
- Are ABBV-RGX-314 Dose 1 clinical trials recruiting in 2026?
- Yes — 3 ABBV-RGX-314 Dose 1 trials are actively recruiting in 2026, with 52 U.S. sites across 20 states. See the recruiting trials and the per-state site list further down this page.
- What conditions is ABBV-RGX-314 Dose 1 being studied for?
- ABBV-RGX-314 Dose 1 is being studied for Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration, AMD, CNV, nAMD and 10 more. The trials are grouped by indication on this page.
- What phase is ABBV-RGX-314 Dose 1 in?
- ABBV-RGX-314 Dose 1 clinical trials span 2 Phase 3, 5 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors ABBV-RGX-314 Dose 1 clinical trials?
- The lead sponsor across the most ABBV-RGX-314 Dose 1 trials is AbbVie, with 2 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming ABBV-RGX-314 Dose 1as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: